SecBot SecBot

EPRX

EUPRAXIA PHARMACEUTICALS INC.
Nasdaq· Pharmaceutical Preparations· Inc. A1· CIK 0001581178 Biotech & Drug Discovery
$6.79 −0.08 (−1.16%)
Oct 26 4:00 PM ET · prev $6.87
Market cap
$500.2M
Small cap
Consensus
Buy
90% Buy or better · 10 analysts
Median target
$16.00
+136% · range $11.00–25.00
1 year
+22.8%
from $5.53 · Oct 27
30 days
−17.3%
from $8.21
52-week range
$5.33–9.10
−25% from high · low Oct 30
Avg volume 20D
965.7K
Oct 1 spike 3.65M
Short interest
6.80M
≈10.3% of shares · −10.3%
Days to cover
11.1
at average volume
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
15
analyzed by SecBot
SecBot read BULLISH 8 reports · 90 days
Balance 1 bearish · 3 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 3/8
Strongest NEUTRAL Eupraxia Pharmaceuticals announced it reached the enrollment target of 120 patients in the Phase 2b…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsBULLISH

    Q2 2026: 8 added (0 new), 3 trimmed or exited.

  • AnalystsBULLISH

    9 of 10 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.244 → −$0.259 over 90 days. 1 up, 1 down in 30 days.

  • Short sellersSTEADY

    Short interest −10.3% to 6.80M shares. 11.1 days to cover, ≈10.3% of shares.

  • TrendDOWNTREND

    10% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
Rubric Capital Management LPADD867,424$5.7M
Woodline Partners LPADD746,864$4.9M
UBS Group AGTRIM519,211$3.4M
CITADEL ADVISORS LLCDOUBLED502,011$3.3M
JANE STREET GROUP, LLCDOUBLED329,053$2.2M
CIBC WORLD MARKET INC.ADD234,673$1.5M
BNP PARIBAS FINANCIAL MARKETSDOUBLED46,145$305.0K
GEODE CAPITAL MANAGEMENT, LLCADD36,211$239.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

10 analysts
Buy 90% rate it Buy or better
Strong Buy4Buy5Hold1Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +136%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Oct 1, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Sep 24, 2026Wedbush
INITIATE
INITIATEOutperform
Jun 26, 2026Oppenheimer
INITIATE
INITIATEOutperform
May 21, 2026Stifel
INITIATE
INITIATEBuy
May 4, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Earnings setup

Estimates
−$0.26
EPS estimate, this quarter
−6%
estimate change, 90 days
1↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.26-$0.32–-$0.22+0.0%$0.00
Next Q-$0.27-$0.36–-$0.21+0.0%$0.00
Current FY-$0.98-$1.16–-$0.78-0.6%$0.00
Next FY-$1.04-$1.31–-$0.38+0.4%$709.8K
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 22, 2026
Press release
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (
Sep 30, 2026
FDA
Eupraxia Pharmaceuticals Reports 52-Week Data from the Highest Dose Cohort of EP-104GI in its Ongoing Phase 1b/2a RESOLVE Trial for the Treatment of Eosinophilic Esophagitis
VANCOUVER, British Columbia, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX)…
Aug 11, 2026
Earnings
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
New data presented at Digestive Disease Week (DDW) demonstrating improvement of fibrosis and inflammation following a single treatment of EP-104GI
Jun 19, 2026
Earnings
Eupraxia Pharmaceuticals Announces Voting Results from Annual General Meeting of Shareholders
VANCOUVER, British Columbia, June 19, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“ Eupraxia ” or the “ Company ”) (TSX: EPRX) (NASDAQ…
May 12, 2026
Earnings
Eupraxia Pharmaceuticals Reports First Quarter 2026 Financial Results
Robust response in highest dose cohort after 36 weeks following a single treatment of EP-104GI

Short side

FINRA· Sep 30, 2026
6,798,798
shares short
-10.3%
vs prior settlement
11.1
days to cover
≈10.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
Eupraxia announced management participation in several upcoming investor conferences and a virtual Analyst Day focused…
6-K — Impact 2/10
Oct 22, 2026 Other
Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
VANCOUVER, British Columbia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (
Oct 15, 2026 SEC
Eupraxia Pharmaceuticals announced it reached the enrollment target of 120 patients in the Phase 2b placebo-controlled…
6-K — Impact 5/10
Oct 9, 2026 SEC
Eupraxia announced that three abstracts from its Phase 1b/2 RESOLVE trial of EP-104GI for eosinophilic esophagitis…
6-K — Impact 4/10
Sep 30, 2026 Press
Eupraxia Pharmaceuticals announced updated Phase 1b/2a RESOLVE data for EP-104GI in Eosinophilic Esophagitis, showing…
Impact 5/10
Jun 30, 2026 Inst.
Rubric Capital Management LP — ADD
867,424 shares ($5.7M)
Jun 30, 2026 Inst.
Woodline Partners LP — ADD
746,864 shares ($4.9M)
Apr 21, 2026 Press
Eupraxia Pharmaceuticals released 36-week data from Cohort 9 of its RESOLVE trial, showing robust and sustained…
Impact 8/10

SecBot reports

15 filings · 3 press releases · 3 bullish · 2 bearish · 10 neutral
All EPRX filing & press-release reports (18)